Oxycodone for managing pain in people with Alzheimer's disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-center, phase 3 interventional trial at Xuanwu Hospital will enroll 10 people with probable Alzheimer's disease and chronic moderate-to-severe pain. Participants will receive oxycodone/acetaminophen (5 mg/325 mg) once daily for 12 weeks with dose adjustments guided by baseline pain and international guidelines. Pain intensity (primary outcome: VAS) and secondary measures (PAINAD, MOBID-2, SF-36, functional ability) plus safety assessments will be recorded at baseline, week 6, week 12, and at a 12-week post-treatment follow-up. The trial includes only participants with a reliable caregiver and requires stable doses of permitted concomitant medications before enrollment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male or female, aged 50 to 90 years at the time of enrollment.
* Meets the NIA-AA core clinical diagnostic criteria for probable Alzheimer's disease.
* Clinical Dementia Rating - Global Score (CDR-GS) between 0.5 and 2.0, inclusive, and Clinical Dementia Rating - Memory Box (CDR-MB) score ≥ 0.5.
* Diagnosed with chronic pain within 6 months prior to enrollment and considered appropriate for opioid therapy.
* Presence and severity of pain confirmed using PAINAD, MOBID-2, or comparable scales.
* Educational attainment: at least 4-6 years of formal education, or not illiterate.
* If currently receiving psychotropic or cognitive-enhancing medications, the dosage must have been stable for at least 3 months prior to study entry and remain unchanged during the study. Unless otherwise specified, all other permitted concomitant medications (non-AD related) must be stably administered for at least 4 weeks prior to baseline.
* Has a reliable caregiver/companion who can assist with study participation, defined as a person who can support the participant throughout the study and spend at least 8 hours per week with the participant.
* Willing and able to participate in this clinical trial, to maintain the assigned intervention during the study period, and has signed the informed consent form.

Exclusion Criteria:

* History of transient ischemic attack (TIA), stroke, or seizure within the past 12 months.
* Presence of any psychiatric diagnosis or symptoms that may interfere with study participation (e.g., hallucinations, major depression, or delusions).
* Known allergy to opioid analgesics.
* Severe visual or hearing impairment.
* Alcohol dependence, substance abuse, or other drug addiction or addictive tendency.
* Current participation in another study related to the treatment of Alzheimer's disease.
* Any other uncontrolled or inadequately treated medical condition (e.g., cardiac, respiratory, gastrointestinal, hepatic, or renal disease), or any condition judged by the investigator to compromise participant safety or interfere with study assessments.
* Any other reason deemed by the investigator to preclude participation in the study.

Where it's running

• Xuanwu Hospital, Capital Medical University
  Beijing, China Recruiting

Study contacts

• Study coordinator: Yi Tang, M.D., Ph.D.
• Email: tangyi@xwhosp.org
• Phone: 00861083199456

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Blood biomarker cohort for memory disorders in older adults

  This observational cohort will collect blood samples and brain imaging data from adults 50+ with memory disorders and a small group of healthy young adults to help find biomarkers.

  Recruiting Yonsei University · Seoul, Seodamun-gu · NCT07880275

• Tau changes after hip or knee replacement surgery

  Researchers will see if brain tau changes after hip or knee surgery and whether these changes relate to inflammation and thinking abilities.

  Recruiting Uppsala University Hospital · Uppsala · NCT07871487

• Low-Dose Whole-Brain Radiation Therapy With HeLaXON 1X in Mild Alzheimer's Dementia

  This study will test whether a low-dose brain radiation treatment using HeLaXON helps people with mild Alzheimer's dementia improve or stabilize thinking and daily function.

  Recruiting ReadyCure Inc. · Cheonan, Chungcheongnam-do · NCT07863011

• Cervical lymphatic surgery to see if it helps people with mild Alzheimer’s

  We’re testing a surgical approach in people with mild Alzheimer’s to see if creating alternative neck lymph drainage routes can affect brain biomarkers and daily function.

  Recruiting at 2 sites Maliszewski Daniel · Gdansk and 1 other locations · NCT07857759

• Transcranial random noise stimulation for behavioral and psychological symptoms in Alzheimer's disease

  This trial tests whether high-frequency transcranial random noise stimulation can help people with early Alzheimer's disease who have BPSD, compared to a sham treatment.

  Recruiting Anhui Medical University · Hefei, Anhui · NCT07827196

• Testing LY4405094 in healthy people and people with Alzheimer’s disease

  This study tests LY4405094 to see if it is safe and how it behaves in the body, including how it reaches the brain fluid in healthy participants and how it affects a brain protein in people with Alzheimer's disease.

  Recruiting Phase 1 Eli Lilly and Company · Anaheim, California and 17 other locations · NCT07787182

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.